,27 Inhibition of MAGL (monoacylglycerol lipase – enzyme degrading endocannabinoid 2-arachidonyl glycerol) has been proposed as a potential therapeutic approach for treatment of diverse neurological and neurodegenerative diseases, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and traumatic brain injury.28 The gene discussed is MGLL; the disease is amyotrophic lateral sclerosis.